Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
The patient took first dose of Vivotif and was due to take second dose yesterday, but missed that dose; Case reference number US-BN-2024-002081 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV24-1437) on 21-Jun-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, or route, for an unknown indication. On an unspecified date, as reported yesterday, an unknown amount of time after the first dose of Vivotif, the patient should take the second dose of Vivotif, but missed that dose (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240621-e32f70 to US-BAVARIAN NORDIC A/S-US-BN-2024-002081, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender should take the second dose of Vivotif, an unknown amount of time after the first dose of Vivotif, but missed that dose, which is considered as missed dose. It was unknown if the patient experienced any adverse event Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown age and gender should take the second dose of Vivotif, an unknown amount of time after the first dose of Vivotif, but missed that dose, which is considered as missed dose. It was unknown if the patient experienced any adverse event Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.